Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost

British Journal of Ophthalmology

Volumn 87, Issue 3, 2003, Pages 297-301

  Kashiwagi, Kenji ^a   Tsukahara, S ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; LATANOPROST; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EROSION; DOSE RESPONSE; GLAUCOMA; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR PRESSURE; MALE; MEASUREMENT; NORMAL HUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLIT LAMP; TONOMETRY; TREATMENT PLANNING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BENZOPHENONES; BROMOBENZENES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC;

EID: 0037341362     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.87.3.297     Document Type: Article

References (41)

1. Alm A. The potential of prostaglandin derivatives in glaucoma therapy. Curr Opin Ophthalmol 1993;4:44-50.
2. Bito LZ. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol 1997;41:S1-14.
3. Camras CB, Alm A. Initial clinical studies with prostaglandins and their anologues. Surv Ophthalmol 1997;41:S61-8.
4. Nilsson SF, Samuelsson M, Bill A, et al. Increased uveosclerol outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989;48:707-16.
5. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandin action on ciliory smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol 1997;41:S53-9.
6. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandins alter extrocellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 1997;3B:2214-23.
7. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997;3B:2772-80.
8. Yousufzai SY, Ye Z, Abdel-Lotif AA. Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res 1996;63:305-10.
9. Kashiwagi K, Tsukamoto K, Suzuki M, et al. Effects of isopropyl unaprostone and latanoprost on melanogenesis in mouse epidermal melonocytes. J Glaucoma 2002;11:57-64.
10. Kashiwagi K, Kanai N, Tsuchida T, et al. Comparison between isopropyl unoprastone and latanoprast by prostaglandin E2 induction, affinity to prostaglandin transporter, and intra-ocular metabolism. Exp Eye Res 2002;74:41-9.
11. Diestelhorst M, Krieglstein GK, Lusky M, et al. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Surv Ophthalmol 1997;41:S77-81.
12. Greve EL, Rulo AH, Drance SM, et al. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprast treatment. Surv Ophthalmol 1997;41:S89-92.
13. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52.
14. Mishima H, Masuda K, Araje M. Long-term study on PhXA41 (latanoprost) ophthalmic solution. Jpn Rev Clin Ophthalmol 1996;90:616-620.
15. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103:126-37.
16. Zhang WY, Po AL, Dua HS, et al. Meta-analysis of randomised controlled trials comparing latanoprast with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001;BS:983-90.
17. Lindsey JD, Kashiwagi K, Boyle D, et al. Prostaglandins increase praMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 1996;15:869-75.
18. Naguchi K, Tominoga Y, Matsushita K, et al. Upregulation of matrix metalloproteinase-1 production by prostaglandin F2 alpha in human gingival fibroblosts. J Periodontal Res 2001;36:334-9.
19. McLaren J, Taylor DJ, Bell SC. Prostaglandin E(2)-dependent production of latent matrix metalloprateinase-9 in cultures of human fetal membranes. Mol Hum Reprod 2000;6:1033-40.
20. Zahner G, Harendza S, Muller E, et al. Prostaglandin E2 stimulates expression of matrix metalloproteinase 2 in cultured rat mesangial cells. Kidney Int 1997;51:1116-23.
21. Kitagawa K, Hayasaka S, Nagaki Y, et al. Effects of tetramethylpyrazine on prostaglandin E(2)- and prostaglandin E(2) receptor agonist-induced disruption of blood-aqueous barrier in pigmented rabbits. Jpn J Ophthalmol 2001;45:227-32
22. Goh Y, Nakajima M, Azuma I, et al. Prostaglandin D2 reduces intraocular pressure. Br J Ophthalmol 1988;72:461-4.
23. Flach AJ, Eliason JA. Topical prostaglandin E2 effects on normal human intraocular pressure. J Ocul Pharmacol Ther1988;4:13-8.
24. Wang RF, Lee PY, Mittag TW, et al. Effect af B-iso prostaglandin E2 on aqueous humor dynamics in monkeys. Arch Ophthalmol 1998;116:1213-6.
25. Serle JB, Wong RF, Mittag TW, et al. Effect of pilocarpine 4% in combination with latanoprost 0.005% or B-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes. J Glaucoma 2001;10:215-9.
26. Sponsel WE, Paris G, Trigo Y, et al. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol 2002;133:11-18.
27. Ogawa T, Sokaue T, Terai T, et al. Effects of bromfenac sodium, non-steroidal anti-inflammatory drug, on acute ocular inflammation (in Japanse). Nippon Ganka Gakkai Zasshi 1995;99:406-11.
28. Sawa M, Masuda K, Usui M, et al. Efficacy of 0.1% bromfenac sodium ophthalmic solution for ocular surface inflammation (Japanese). Ganki 1997;48:717-24.
29. Moreno JJ. Arachidonic acid release and prostaglandin E2 synthesis as irritant index of surfactants in 3T6 fibroblast cultures. Toxicology 2000;143:275-82.
30. Jorgensen HP, Sondergaard J. Biosynthesis of prostaglandins by human inflamed skin. Acta Derm Venereol 1976;S6:11-3.
31. DuBiner HB, Mroz M, Shapiro AM, et al. A camparison of the efficocy and tolerability of brimonidine and latanoprost in adults with apen-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 2001;23:1969-83
32. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41:S129-38.
33. Chiba T, Kashiwagi K, Kogure S, et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma 2001;10:406-10.
34. Ogawa I, Imai K. Iridial pigmentaion and hypertrichosis of eyelids caused by latanoprost instillation (in Japanese). J Eye 2000;17:429-33.
35. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37-41.
36. Warwar RE, Bullock JD, Ballal D. Cystoid macular edemo and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;10S:263-8.
37. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid maculor edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998;126:602-4.
38. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998;126:134-5.
39. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999;106:1024-9.
40. Tokunaga T, Kashiwagi K, Saito J, et al. A Case of cystoid maculor edema associated with latanoprost ophthalmic solution. Jpn J Ophthalmol 2002;46:656-9.
41. Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudaphakias. Arch Ophthalmol 1999;117:34-40.